IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  Comparison	
  between	
  single	
  shot	
  peripheral	
  nerve	
  block	
  and	
  continuous	
  infusion	
  via	
  a	
  On-­‐Q	
  Pump:	
  a	
  randomized	
  prospective	
  control	
  trial	
  	
  	
  	
  	
  Principal	
  Investigator:	
  	
  Nirmal	
  Tejwani,	
  MD	
  	
  	
  Co-­‐investigators:	
  David	
  Ding,	
  MD	
  Sudheer	
  Jain,	
  M.D.	
  David	
  Taormina,	
  BS	
  	
  	
  	
  	
  	
  Department	
  of	
  Orthopaedic	
  Surgery	
  NYU-­‐Hospital	
  for	
  Joint	
  Diseases	
  301	
  East	
  17th	
  Street	
  New	
  York,	
  NY	
  10003	
  	
  	
  	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  Brief	
  Summary	
  Peripheral	
  nerve	
  blocks	
  have	
  been	
  well	
  studied	
  in	
  the	
  literature	
  with	
  generally	
  good	
  results	
  for	
  controlling	
  post	
  operative	
  pain	
  following	
  orthopaedic	
  surgery.	
  	
  Regional	
  anesthesia	
  has	
  many	
  benefits.	
  	
  It	
  provides	
  excellent	
  intraoperative	
  anesthesia	
  and	
  muscle	
  relaxation	
  as	
  well	
  as	
  analgesia	
  that	
  continues	
  into	
  the	
  post-­‐operative	
  period.	
  	
  These	
  regional	
  blocks	
  are	
  also	
  effective	
  in	
  controlling	
  pain	
  in	
  the	
  immediate	
  post-­‐operative	
  period.	
  However,	
  as	
  the	
  block	
  wears	
  off,	
  patients	
  begin	
  experiencing	
  increased	
  pain.	
  Compared	
  to	
  patients	
  treated	
  without	
  regional	
  blocks,	
  these	
  patients	
  will	
  often	
  experience	
  a	
  "rebound	
  pain"-­‐-­‐pain	
  occurring	
  12-­‐24	
  hours	
  after	
  surgery	
  that	
  is	
  subjectively	
  worse	
  than	
  that	
  in	
  patients	
  treated	
  without	
  regional	
  blocks.	
  Therefore,	
  we	
  propose	
  to	
  use	
  a	
  continuous	
  infusion	
  of	
  anesthetic	
  in	
  order	
  to	
  provide	
  sustained	
  pain	
  control	
  post-­‐operatively.	
  Preoperatively,	
  patients	
  will	
  be	
  randomized	
  into	
  a	
  single	
  shot	
  peripheral	
  nerve	
  block	
  versus	
  a	
  continuous	
  infusion	
  of	
  peripheral	
  nerve	
  block.	
  	
  	
  Post-­‐operatively,	
  pain	
  will	
  be	
  assessed	
  using	
  the	
  Visual	
  Analogue	
  Scale	
  (1-­‐100)	
  prior	
  to	
  being	
  discharged	
  from	
  PACU.	
  Time	
  to	
  discharge	
  and	
  amount	
  of	
  pain	
  medication	
  taken	
  will	
  be	
  recorded.	
  Patients	
  will	
  be	
  contacted	
  at	
  certain	
  time	
  intervals	
  postoperatively	
  to	
  assess	
  their	
  pain	
  scale	
  and	
  pain	
  medication	
  intake.	
  Patients	
  will	
  be	
  seen	
  for	
  routine	
  post-­‐operative	
  follow-­‐up	
  visits	
  where	
  they	
  will	
  be	
  assessed	
  for	
  satisfaction,	
  pain,	
  residual	
  neurological	
  symptoms,	
  and	
  signs	
  of	
  infection.	
  	
  	
  Purpose	
  The	
  purpose	
  of	
  this	
  randomized	
  prospective	
  study	
  will	
  be	
  to	
  compare	
  post-­‐operative	
  pain	
  control	
  after	
  extremity	
  fracture	
  fixation	
  surgery	
  between	
  patients	
  who	
  receive	
  single	
  shot	
  versus	
  continuous	
  peripheral	
  nerve	
  blocks.	
  	
  Scientific	
  or	
  Scholarly	
  Rationale	
  Peripheral	
  nerve	
  blocks	
  have	
  been	
  well	
  studied	
  in	
  the	
  literature	
  with	
  generally	
  good	
  results	
  for	
  controlling	
  post	
  operative	
  pain	
  following	
  orthopaedic	
  surgery	
  1-­‐4.  Regional	
  anesthesia	
  has	
  many	
  benefits.	
  	
  It	
  provides	
  excellent	
  intraoperative	
  anesthesia	
  and	
  muscle	
  relaxation	
  as	
  well	
  as	
  analgesia	
  that	
  continues	
  into	
  the	
  post-­‐operative	
  period.	
  	
  Airway	
  manipulations	
  are	
  avoided,	
  post-­‐operative	
  nausea	
  and	
  vomiting	
  are	
  diminished,	
  post-­‐anesthesia	
  care	
  unit	
  stay	
  are	
  shortened,	
  and	
  fewer	
  nursing	
  interventions	
  in	
  the	
  post-­‐anesthesia	
  care	
  unit	
  are	
  required5-­‐6.	
  	
  Patients	
  who	
  have	
  operative	
  fixation	
  of	
  extremity	
  fractures	
  (ankle,	
  wrist,	
  forearm)	
  are	
  typically	
  ambulatory	
  patients.	
  	
  However,	
  many	
  become	
  hospitalized	
  overnight	
  secondary	
  to	
  inadequate	
  pain	
  control,	
  increasing	
  hospital	
  costs.	
  	
  Goldstein	
  et	
  al.	
  showed	
  that	
  patients who underwent popliteal blocks after ankle fracture fixation demonstrated significantly better pain control immediately postoperatively7. The	
  need	
  for	
  overnight	
  hospitalization	
  secondary	
  to	
  pain	
  is	
  decreased,	
  as	
  are	
  nonsurgical	
  operating	
  room	
  times.	
  	
   Despite	
  the	
  success	
  of	
  regional	
  anesthesia,	
  a	
  phenomenon	
  known	
  as	
  “rebound	
  pain”	
  has	
  been	
  shown	
  to	
  occur	
  as	
  the	
  original	
  block	
  wears	
  off7-­‐9.	
  	
  Patients	
  with	
  blocks	
  will	
  experience	
  significantly	
  increased	
  pain	
  compared	
  to	
  those	
  without	
  blocks	
  approximately	
  12-­‐24	
  hours	
  after	
  surgery.	
  This	
  can	
  be	
  controlled	
  with	
  early	
  narcotic	
  administration	
  but	
  can	
  be	
  a	
  source	
  of	
  significant	
  discomfort	
  to	
  a	
  patient	
  if	
  not	
  recognized	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  and	
  treated	
  in	
  time.	
  	
  	
  A	
  few	
  studies	
  have	
  shown	
  that	
  continuous	
  infusions	
  of	
  various	
  numbing	
  agents	
  are	
  efficacious	
  in	
  prolonged	
  pain	
  control,	
  even	
  in	
  the	
  ambulatory	
  setting10-­‐12.	
  	
  	
  Nevertheless,	
  no	
  studies	
  have	
  thus	
  performed	
  a	
  randomized	
  prospective	
  control	
  trial	
  studying	
  the	
  efficacy	
  of	
  continuous	
  infusion	
  therapy	
  on	
  pain	
  control	
  following	
  extremity	
  fracture	
  surgery.	
  	
  Aims	
  1. To	
  determine	
  the	
  effectiveness	
  of	
  continuously	
  infused	
  regional	
  anesthetic	
  for	
  pain	
  control	
  in	
  extremity	
  fracture	
  surgery	
  2. To	
  determine	
  the	
  effect	
  of	
  rebound	
  pain	
  on	
  patient	
  satisfaction	
  of	
  surgery	
  Description	
  of	
  study	
  and	
  study	
  procedure	
  Consent	
  All	
  patients	
  being	
  treated	
  with	
  open	
  reduction	
  internal	
  fixation	
  for	
  foot,	
  ankle,	
  tibia,	
  elbow,	
  forearm	
  and	
  wrist	
  fractures	
  at	
  New	
  York	
  University	
  Medical	
  Center,	
  NYU-­‐Hospital	
  for	
  Joint	
  Diseases	
  will	
  be	
  asked	
  to	
  participate	
  in	
  this	
  study.	
  	
  At	
  the	
  patients	
  preoperative	
  office	
  visit,	
  they	
  will	
  be	
  asked	
  to	
  participate	
  in	
  the	
  study	
  and	
  provided	
  a	
  copy	
  of	
  the	
  consent	
  form	
  at	
  that	
  time	
  which	
  they	
  can	
  take	
  home	
  with	
  them.	
  All	
  questions	
  will	
  be	
  answered	
  and	
  they	
  will	
  be	
  asked	
  verbally	
  if	
  they	
  will	
  consent	
  to	
  being	
  a	
  part	
  of	
  the	
  study.	
  Patients	
  will	
  then	
  have	
  the	
  opportunity	
  to	
  either	
  sign	
  the	
  written	
  consent	
  forms	
  or	
  wait	
  till	
  the	
  surgical	
  date	
  to	
  think	
  about	
  the	
  study	
  and	
  any	
  additional	
  questions	
  they	
  may	
  have.	
  At	
  the	
  time	
  of	
  surgery,	
  patients	
  will	
  be	
  consented	
  for	
  surgery.	
  	
  If	
  the	
  patient	
  did	
  not	
  give	
  written	
  consent	
  at	
  the	
  preoperative	
  visit,	
  they	
  will	
  be	
  asked	
  if	
  they	
  have	
  any	
  questions	
  about	
  the	
  study.	
  All	
  questions	
  will	
  again	
  be	
  answered.	
  They	
  will	
  then	
  be	
  asked	
  verbally	
  if	
  they	
  are	
  willing	
  to	
  participate	
  in	
  the	
  study,	
  if	
  they	
  respond	
  yes,	
  then	
  written	
  consent	
  will	
  be	
  obtained	
  at	
  that	
  time.	
  Randomization	
  	
  Patients	
  will	
  then	
  be	
  randomized	
  (using	
  an	
  online	
  randomizer,	
  similar	
  to	
  a	
  flip	
  of	
  a	
  coin)	
  to	
  one	
  of	
  two	
  anesthetic	
  protocols:	
  regional	
  block	
  with	
  single	
  dose	
  of	
  anesthetic	
  versus	
  regional	
  block	
  with	
  continuous	
  infusion	
  using	
  an	
  OnQ	
  pump.	
  If	
  for	
  some	
  reason,	
  the	
  anesthesiologist	
  feels	
  that	
  a	
  patient	
  would	
  benefit	
  from	
  one	
  type	
  of	
  anesthesia	
  	
  over	
  another,	
  the	
  patient	
  will	
  be	
  removed	
  from	
  the	
  study	
  and	
  given	
  that	
  type	
  of	
  anesthesia.	
  Intervention	
  Patients	
  will	
  be	
  randomized	
  to	
  one	
  of	
  two	
  anesthetic	
  protocols:	
  	
  general	
  anesthesia/sedation	
  with	
  a	
  single	
  shot,	
  peripheral	
  nerve	
  block	
  versus	
  general	
  anesthesia/sedation	
  with	
  a	
  continuous,	
  peripheral	
  nerve	
  block.	
  	
  All	
  anesthesia	
  will	
  be	
  provided	
  by	
  an	
  attending	
  anesthesiologist	
  with	
  or	
  without	
  an	
  anesthesiology	
  resident/CRNA.	
  	
  Patients	
  will	
  have	
  standard	
  ASA	
  monitors	
  placed	
  (pulse	
  oximeter,	
  blood	
  pressure,	
  EKG)	
  and	
  an	
  intravenous	
  line	
  started.	
  	
  Sedation	
  will	
  be	
  given	
  using	
  a	
  combination	
  of	
  midazolam	
  (1-­‐4	
  mg)	
  and	
  fentanyl	
  (25-­‐100	
  mcg).	
  	
  Patients	
  in	
  both	
  groups	
  will	
  receive	
  an	
  ultrasound-­‐guided	
  peripheral	
  nerve	
  block.	
  	
  The	
  block	
  will	
  be	
  either	
  an	
  infraclavicular	
  brachial	
  plexus	
  block	
  or	
  a	
  popliteal	
  nerve	
  block,	
  depending	
  on	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  the	
  location	
  of	
  the	
  fracture.	
  	
  The	
  appropriate	
  region	
  will	
  be	
  prepped	
  with	
  a	
  chlorohexidine	
  solution	
  on	
  the	
  appropriate	
  surgical	
  side	
  and	
  the	
  appropriate	
  site	
  will	
  be	
  visualized	
  under	
  ultrasound.	
  	
  For	
  the	
  group	
  receiving	
  a	
  single	
  shot	
  block,	
  a	
  22	
  gauge,	
  3.5	
  inch	
  needle	
  will	
  be	
  used	
  and	
  20cc	
  of	
  2%	
  lidocaine	
  with	
  1:200,000	
  epinephrine	
  +	
  20	
  cc	
  of	
  0.5%	
  bupivacaine	
  with	
  1:300,000	
  epinephrine	
  will	
  be	
  injected	
  around	
  the	
  nerve	
  after	
  confirming	
  negative	
  aspiration	
  every	
  5	
  cc.	
  	
  For	
  those	
  receiving	
  a	
  continuous	
  infusion,	
  a	
  17	
  gauge	
  Tuohy	
  needle	
  will	
  be	
  used	
  and	
  20cc	
  of	
  2%	
  lidocaine	
  with	
  epinephrine	
  +	
  20	
  cc	
  of	
  0.5%	
  bupivacaine	
  with	
  1:300,000	
  epinephrine	
  will	
  be	
  injected	
  around	
  the	
  nerve	
  after	
  confirming	
  negative	
  aspiration	
  every	
  5cc.	
  	
  Once	
  the	
  injection	
  is	
  complete,	
  an	
  indwelling	
  catheter	
  will	
  be	
  placed	
  with	
  its	
  tip	
  location	
  confirmed	
  and	
  then	
  secured	
  at	
  the	
  skin.	
  	
  After	
  placement	
  of	
  the	
  regional	
  block,	
  general	
  anesthesia/sedation	
  will	
  be	
  administered	
  and	
  maintained	
  at	
  the	
  discretion	
  of	
  the	
  anesthesiologist.	
  	
  Induction	
  of	
  anesthesia	
  will	
  involve	
  IV	
  propofol	
  (2mg/kg)	
  and	
  fentanyl	
  (1-­‐2mcg/kg).	
  	
  Neuromuscular	
  blockade	
  will	
  be	
  used	
  at	
  the	
  discretion	
  of	
  the	
  anesthesiologist	
  and	
  will	
  be	
  reversed	
  appropriately.	
  	
  Anesthetic	
  maintenance	
  will	
  involve	
  inhalational	
  agents,	
  IV	
  agents,	
  air,	
  and	
  oxygen.	
  	
  Fentanyl	
  will	
  be	
  the	
  only	
  intraoperative	
  analgesic	
  used	
  and	
  will	
  be	
  dosed	
  as	
  determined	
  by	
  the	
  anesthesiologist.	
  	
  After	
  completion	
  of	
  the	
  surgery,	
  patients	
  will	
  be	
  taken	
  to	
  the	
  PACU	
  where	
  those	
  with	
  continuous	
  catheters	
  will	
  have	
  an	
  OnQ	
  pump	
  attached	
  to	
  it.	
  	
  The	
  patient	
  will	
  begin	
  receiving	
  a	
  continuous	
  infusion	
  of	
  0.2%	
  ropivacaine	
  through	
  the	
  catheter	
  at	
  a	
  rate	
  of	
  8	
  cc/hr.	
  	
  The	
  patient	
  will	
  be	
  discharged	
  home	
  with	
  the	
  catheter	
  for	
  48	
  hours.	
  	
  The	
  study	
  participant	
  will	
  self-­‐discontinue	
  the	
  catheter	
  in	
  2	
  days.	
  	
  This	
  involves	
  removing	
  the	
  tegaderm	
  dressing	
  and	
  gently	
  pulling	
  the	
  catheter	
  out	
  from	
  under	
  the	
  skin.	
  	
  A	
  bandage	
  may	
  then	
  be	
  applied.	
  	
  Germaine	
  Cuff,	
  our	
  anesthesiology	
  RN,	
  will	
  be	
  available	
  via	
  phone	
  to	
  answer	
  any	
  questions	
  study	
  participants	
  may	
  have	
  regarding	
  discontinuation	
  of	
  the	
  catheter.	
  	
  Breakthrough	
  pain	
  while	
  in	
  the	
  PACU	
  will	
  be	
  treated	
  with	
  IV	
  fentanyl	
  and	
  PO	
  Percocet	
  as	
  needed.	
  	
  Postoperatively,	
  all	
  patients	
  will	
  be	
  discharged	
  home	
  with	
  a	
  prescription	
  for	
  Percocet	
  5/325	
  with	
  instructions	
  to	
  take	
  1-­‐2	
  tabs	
  every	
  4-­‐6hrs	
  as	
  needed	
  for	
  pain.	
  Data	
  collection	
  Location	
  and	
  type	
  of	
  surgical	
  procedure,	
  duration	
  of	
  procedure,	
  and	
  duration	
  of	
  intravenous	
  sedation	
  will	
  also	
  be	
  recorded.	
  	
  Total	
  time	
  in	
  the	
  operating	
  room	
  will	
  also	
  be	
  noted.	
  Time	
  admitted	
  to	
  PACU,	
  time	
  clinically	
  ready	
  for	
  discharge,	
  time	
  actually	
  discharge,	
  PACU	
  medications	
  for	
  nausea/vomiting	
  and	
  PACU	
  meds	
  for	
  pain	
  will	
  all	
  be	
  recorded	
  prior	
  to	
  discharge.	
  Post-­‐operative	
  pain	
  will	
  be	
  assessed	
  using	
  the	
  Visual	
  Analogue	
  Scale	
  (0-­‐100)	
  prior	
  to	
  being	
  discharged	
  from	
  PACU.	
  Time	
  to	
  discharge	
  and	
  amount	
  of	
  pain	
  medication	
  taken	
  in	
  the	
  PACU	
  will	
  be	
  recorded.	
  Patients	
  	
  will	
  be	
  contacted	
  8	
  hours,	
  12	
  hours,	
  24	
  hours,	
  48	
  hours	
  and	
  72hrs	
  after	
  surgery	
  by	
  the	
  operative	
  surgeon	
  or	
  research	
  coordinator	
  to	
  assess	
  their	
  pain	
  scale	
  and	
  pain	
  medication	
  intake.	
  Patients	
  will	
  be	
  seen	
  for	
  routine	
  post-­‐operative	
  follow-­‐up	
  visits	
  at	
  two,	
  six,	
  twelve,	
  twenty-­‐four,	
  and	
  fifty-­‐two	
  weeks.	
  At	
  these	
  times,	
  patients	
  will	
  be	
  assessed	
  for	
  pain,	
  residual	
  neurological	
  symptoms,	
  and	
  signs	
  of	
  infection.	
  	
  Patients	
  will	
  also	
  be	
  asked	
  if	
  they	
  were	
  satisfied	
  with	
  their	
  postoperative	
  pain	
  control.	
  Total	
  duration	
  of	
  study	
  will	
  be	
  fifty-­‐two	
  weeks.	
  	
  Data	
  collection	
  documents	
  will	
  be	
  distributed	
  to	
  the	
  patients	
  at	
  time	
  of	
  surgery	
  to	
  assist	
  in	
  patient	
  understanding.	
  	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  Inclusion	
  criteria	
  1. Patients	
  at	
  least	
  18	
  years	
  old.	
  2. Male	
  or	
  Female	
  	
  3. All	
  racial	
  and	
  ethnic	
  groups	
  4. Fractures	
  and	
  fracture/dislocations	
  of	
  the	
  foot,	
  ankle,	
  tibia,	
  fibula,	
  elbow,	
  forearm,	
  wrist	
  and	
  hand	
  5. Patients	
  who	
  opt	
  for	
  surgical	
  treatment	
  of	
  their	
  fractures.	
  6. Patients	
  who	
  consent	
  to	
  be	
  randomized.	
  7. Patients	
  who	
  are	
  willing	
  to	
  follow-­‐up	
  for	
  a	
  minimum	
  of	
  52	
  weeks.	
  Exclusion	
  criteria	
  1. Patients	
  younger	
  than	
  18	
  years	
  old.	
  2. Patients	
  who	
  are	
  on	
  chronic	
  opioids	
  3. Patients	
  who	
  abuse	
  opioids	
  4. Patients	
  who	
  are	
  unwilling	
  to	
  follow-­‐up	
  for	
  a	
  minimum	
  of	
  52	
  weeks.	
  5. Neurologic	
  condition	
  that	
  could	
  interfere	
  with	
  pain	
  sensation	
  	
  Characteristics	
  of	
  the	
  Research	
  Population	
  1. Total	
  number	
  of	
  subjects:	
  100	
  subjects	
  2. Gender:	
  Male	
  or	
  Female	
  3. Racial	
  and	
  Ethnic	
  Origins:	
  All	
  are	
  included	
  	
  Study	
  payments/cost:	
  	
  Study	
  participants	
  will	
  not	
  incur	
  any	
  additional	
  costs	
  or	
  payments	
  as	
  a	
  result	
  of	
  this	
  study.	
  	
  Any	
  additional	
  costs	
  will	
  be	
  absorbed	
  by	
  the	
  NYU	
  Departments	
  of	
  Orthopaedics	
  and	
  Anesthesia	
  Potential	
  Risks	
  and	
  Discomforts:	
  	
  	
  The	
  research-­‐related	
  complications	
  associated	
  with	
  regional	
  block	
  include,	
  but	
  are	
  not	
  limited	
  to,	
  intravascular	
  injection,	
  local	
  anesthetic	
  toxicity,	
  hematoma	
  formation	
  around	
  insertion	
  site,	
  infection	
  around	
  injection	
  site,	
  permanent	
  or	
  temporary	
  nerve	
  injury,	
  and	
  allergic	
  reactions	
  to	
  the	
  medication	
  injected.	
  The	
  research-­‐related	
  complications	
  associated	
  with	
  the	
  On-­‐Q	
  pump	
  include,	
  but	
  are	
  not	
  limited	
  to,	
  site	
  infection,	
  superficial	
  nerve	
  injury,	
  and	
  local	
  anesthetic	
  toxicity.	
  	
  There	
  may	
  be	
  additional	
  risk	
  of	
  injury	
  in	
  the	
  On-­‐Q	
  pump	
  Group,	
  if	
  participants	
  resume	
  regular	
  activities,	
  prematurely,	
  while	
  free	
  of	
  pain.	
  There	
  may	
  be	
  unknown	
  risks/discomforts	
  involved.	
  	
  Study	
  staff	
  will	
  update	
  all	
  patients	
  in	
  a	
  timely	
  way	
  on	
  any	
  new	
  information	
  that	
  may	
  affect	
  the	
  patients’	
  health,	
  welfare,	
  or	
  decision	
  to	
  remain	
  in	
  the	
  study.	
  	
  If	
  the	
  patients	
  have	
  any	
  questions	
  or	
  sustain	
  any	
  injury	
  during	
  the	
  course	
  of	
  the	
  research	
  or	
  experience	
  any	
  adverse	
  reaction	
  to	
  one	
  of	
  the	
  surgical	
  treatments	
  they	
  will	
  be	
  informed	
  during	
  the	
  process	
  of	
  obtaining	
  informed	
  consent	
  that	
  they	
  should	
  contact	
  the	
  Principal	
  Investigator	
  Dr.	
  Nirmal	
  Tejwani	
  at	
  the	
  following	
  telephone	
  number	
  212-­‐598-­‐6599.	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  In	
  addition,	
  if	
  there	
  is	
  any	
  Adverse	
  Event	
  that	
  occurs	
  during	
  the	
  study,	
  then	
  the	
  Principal	
  Investigator	
  will	
  make	
  the	
  IRB	
  aware	
  of	
  this.	
  	
  The	
  Principal	
  Investigator	
  will	
  submit	
  a	
  Reportable	
  Events	
  Form	
  for	
  all	
  reportable	
  information	
  to	
  the	
  IRB	
  within	
  5	
  working	
  days	
  from	
  when	
  the	
  Principal	
  Investigator	
  learns	
  of	
  the	
  event	
  or	
  new	
  information.	
  Potential	
  Benefits:	
  	
  The	
  patients	
  are	
  not	
  likely	
  to	
  receive	
  any	
  direct	
  benefit	
  from	
  their	
  participation	
  in	
  this	
  study	
  aside	
  from	
  possible	
  increased	
  pain	
  relief	
  after	
  operative	
  fixation	
  of	
  their	
  fracture.	
  	
  However,	
  the	
  patients’	
  participation	
  may	
  help	
  the	
  investigators	
  better	
  understand	
  the	
  best	
  post-­‐operative	
  pain	
  protocol	
  for	
  extremity	
  fracture	
  fixation.	
  	
  In	
  addition,	
  the	
  patients’	
  participation	
  may	
  help	
  the	
  investigators	
  better	
  understand	
  if	
  there	
  is	
  any	
  prolonged	
  benefit	
  to	
  with	
  one	
  post-­‐operative	
  treatment	
  over	
  the	
  other,	
  which	
  could	
  thereby	
  give	
  orthopaedic	
  surgeons	
  conclusive	
  evidence	
  of	
  the	
  best	
  post-­‐operative	
  pain	
  protocol	
  for	
  operative	
  fractures	
  about	
  the	
  forearm	
  and	
  wrist	
  that	
  could	
  also	
  translate	
  into	
  better	
  patient	
  satisfaction.	
  	
  	
  Data	
  Monitoring	
  Plan:	
  	
  1. Types	
  of	
  data	
  or	
  events:	
  	
  a. Intravascular	
  injection	
  	
  b. local	
  anesthetic	
  toxicity	
  	
  c. hematoma	
  formation	
  	
  d. Infection	
  e. Neurologic	
  injury	
  f. Allergic	
  reaction	
  2. Responsibilities	
  and	
  roles	
  for	
  gathering,	
  evaluating	
  and	
  monitoring	
  the	
  data:	
  a. All	
  data	
  (including	
  details	
  about	
  adverse/unexpected	
  events)	
  will	
  be	
  collected	
  by	
  the	
  operative	
  team	
  or	
  research	
  coordinator	
  at	
  specific	
  time	
  points:	
  8hrs	
  post-­‐op,	
  24hr,	
  48hr,	
  72hrs,	
  2wks,	
  6wks,	
  12wks,	
  24wks	
  and	
  52wks	
  and	
  reported	
  to	
  the	
  research	
  coordinator	
  using	
  standard	
  templated	
  data	
  collection	
  forms.	
  All	
  patients	
  will	
  be	
  told	
  to	
  call	
  Dr.	
  Nirmal	
  Tejwani	
  at	
  212-­‐598-­‐6599	
  to	
  report	
  adverse	
  reactions	
  during	
  the	
  study.	
  	
  b. All	
  data	
  will	
  be	
  verified	
  by	
  the	
  research	
  team	
  and	
  coordinator	
  for	
  accuracy	
  and	
  compliance	
  with	
  the	
  protocol	
  at	
  each	
  time	
  point	
  as	
  designated	
  above.	
  3. Information	
  about	
  the	
  monitoring	
  entity:	
  a. Principle	
  investigator	
  Dr.	
  Nirmal	
  Tejwani,	
  Dr.	
  Sudheer	
  Jain,	
  and	
  Dr.	
  David	
  Ding	
  comprise	
  the	
  monitoring	
  entity.	
  	
  4. Reporting	
  Adverse	
  events	
  and	
  Unanticipated	
  problems	
  to	
  the	
  monitoring	
  entity:	
  a. The	
  Principal	
  Investigator	
  will	
  submit	
  a	
  Reportable	
  Events	
  Form	
  for	
  all	
  reportable	
  information	
  to	
  the	
  IRB	
  within	
  5	
  working	
  days	
  from	
  when	
  the	
  Principal	
  Investigator	
  learns	
  of	
  the	
  event	
  or	
  new	
  information.	
  5. Assessments:	
  a. The	
  Monitoring	
  entity	
  will	
  review	
  data	
  monthly	
  and	
  assess	
  the	
  data	
  for	
  unanticipated	
  problems	
  involving	
  risks	
  to	
  participants.	
  6. Criteria	
  for	
  Action:	
  a. Specific	
  triggers	
  for	
  action	
  include	
  any	
  event	
  that	
  is	
  deemed	
  to	
  be	
  a	
  risk	
  to	
  life	
  or	
  limb.	
  	
  7. Procedure	
  for	
  communicating:	
  	
  a. The	
  Principal	
  Investigator	
  will	
  submit	
  a	
  Reportable	
  Events	
  Form	
  for	
  all	
  reportable	
  information	
  to	
  the	
  IRB	
  within	
  5	
  working	
  days	
  from	
  when	
  the	
  Principal	
  Investigator	
  learns	
  of	
  the	
  event	
  or	
  new	
  information.	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  	
  Data	
  Storage	
  and	
  Confidentiality:	
  All	
  patients	
  will	
  be	
  de-­‐identified	
  and	
  given	
  a	
  code.	
  Information	
  linking	
  the	
  linkage	
  codes	
  to	
  the	
  participants’	
  names,	
  social	
  security	
  numbers	
  and	
  medical	
  record	
  numbers	
  will	
  be	
  stored	
  in	
  a	
  secure	
  location	
  separate	
  from	
  the	
  medical	
  information.	
  	
  Access	
  to	
  the	
  information	
  linking	
  the	
  linkage	
  codes	
  with	
  participant	
  identifiers	
  shall	
  be	
  documented.	
  	
  The	
  patient’s	
  informed	
  consent	
  will	
  be	
  obtained	
  in	
  one	
  of	
  the	
  exam	
  rooms	
  in	
  the	
  private	
  office.	
  Participant	
  medical	
  information	
  will	
  be	
  stored	
  electronically	
  within	
  a	
  password	
  protected	
  spreadsheet	
  available	
  only	
  to	
  the	
  PI,	
  co-­‐investigators,	
  and	
  research	
  staff	
  as	
  necessary	
  for	
  data	
  analysis.	
  	
  The	
  names,	
  social	
  security	
  numbers,	
  and	
  medical	
  record	
  numbers	
  of	
  the	
  study	
  participants	
  will	
  be	
  deleted	
  from	
  their	
  stored	
  medical	
  information	
  and	
  replaced	
  with	
  a	
  linkage	
  code.	
  	
  Access	
  to	
  participant	
  medical	
  information	
  contained	
  within	
  the	
  registry	
  will	
  be	
  restricted.	
  Protection	
  Against	
  Risk:	
  All	
  procedures	
  will	
  be	
  performed	
  as	
  outlined	
  above.	
  After	
  the	
  procedure	
  pt	
  will	
  be	
  contacted	
  6-­‐8	
  hours	
  after	
  surgery	
  and	
  at	
  24	
  hours,	
  48	
  hours	
  and	
  72hours	
  after	
  surgery	
  by	
  the	
  operative	
  surgeon	
  or	
  research	
  coordinator	
  to	
  assess	
  their	
  pain	
  scale	
  and	
  pain	
  medication	
  intake.	
  Patients	
  will	
  be	
  seen	
  for	
  routine	
  post-­‐operative	
  follow-­‐up	
  visits	
  at	
  two,	
  six,	
  twelve,	
  twenty-­‐four,	
  and	
  fifty-­‐two	
  weeks.	
  At	
  these	
  times,	
  patients	
  will	
  be	
  assessed	
  for	
  pain,	
  residual	
  neurological	
  symptoms,	
  and	
  signs	
  of	
  infection,	
  and	
  starting	
  at	
  the	
  six	
  week	
  time	
  point,	
  patient's	
  functional	
  status	
  will	
  be	
  assessed	
  using	
  the	
  Disability	
  of	
  the	
  Arm,	
  Shoulder	
  and	
  Hand	
  (DASH)	
  and	
  SMFA	
  scores,	
  both	
  are	
  widely	
  accepted	
  and	
  validated	
  functional	
  measures.	
  Method	
  of	
  Subject	
  Identification	
  and	
  Recruitment:	
  All	
  patients	
  seen	
  in	
  the	
  outpatient	
  office,	
  who	
  fit	
  the	
  inclusion	
  criteria	
  will	
  be	
  asked	
  to	
  participate	
  in	
  the	
  study.	
  	
  Subject/Representative	
  Comprehension:	
  None	
  Debriefing	
  Procedures:	
  All	
  patients	
  will	
  have	
  regular	
  follow-­‐up	
  at	
  which	
  point,	
  all	
  questions	
  regarding	
  the	
  study	
  can	
  be	
  answered.	
  	
  Documentation	
  of	
  Consent:	
  A	
  copy	
  of	
  the	
  signed	
  consent	
  form	
  will	
  be	
  securely	
  kept	
  for	
  our	
  records.	
  Statistical	
  analysis	
  plan:	
  	
  A	
  preoperative	
  power	
  analysis	
  was	
  performed.	
  	
  On	
  a	
  VAS	
  scaled	
  from	
  1-­‐100,	
  assuming	
  a	
  standard	
  deviation	
  of	
  20,	
  the	
  number	
  needed	
  to	
  detect	
  a	
  10	
  point	
  changed	
  in	
  VAS	
  was	
  38.	
  Assuming	
  a	
  drop	
  out	
  rate	
  of	
  20%,	
  we	
  will	
  require	
  50	
  patients	
  in	
  each	
  group	
  to	
  determine	
  significance.	
  	
  	
  The	
  primary	
  end	
  points	
  of	
  the	
  study	
  for	
  Visual	
  Analog	
  Score	
  will	
  be	
  assess	
  using	
  two-­‐group	
  t-­‐tests	
  (Mann-­‐Whitney	
  U	
  test	
  where	
  appropriate).	
  	
  Amount	
  of	
  pain	
  medication	
  utilized	
  post	
  operatively	
  will	
  be	
  assessed	
  using	
  Student	
  t-­‐tests.	
  	
  Residual	
  neurological	
  symptoms	
  and	
  signs	
  of	
  infection	
  will	
  be	
  reported	
  as	
  descriptive	
  statistics.	
  	
  Descriptive	
  statistics	
  will	
  be	
  reported	
  as	
  means	
  +/-­‐	
  SD	
  for	
  continuous	
  variables	
  and	
  as	
  frequencies	
  and	
  percentages	
  for	
  categorical	
  variables.	
  	
  	
  
IRB #S12-03598 	
  
Version:	
  12-­‐18-­‐12	
  	
  References	
  1.	
  Rukewe	
  A,	
  Adeoye,	
  II,	
  Sule	
  UM,	
  Fatiregun	
  A.	
  Interscalene	
  block	
  for	
  shoulder	
  surgery.	
  Ann	
  Afr	
  Med.	
  Apr-­‐Jun	
  2011;10(2):185-­‐187.	
  2.	
  Hunt	
  KJ,	
  Higgins	
  TF,	
  Carlston	
  CV,	
  Swenson	
  JR,	
  McEachern	
  JE,	
  Beals	
  TC.	
  Continuous	
  peripheral	
  nerve	
  blockade	
  as	
  postoperative	
  analgesia	
  for	
  open	
  treatment	
  of	
  calcaneal	
  fractures.	
  J	
  Orthop	
  Trauma.	
  Mar	
  2010;24(3):148-­‐155.	
  3.	
  de	
  Visme	
  V,	
  Picart	
  F,	
  Le	
  Jouan	
  R,	
  Legrand	
  A,	
  Savry	
  C,	
  Morin	
  V.	
  Combined	
  lumbar	
  and	
  sacral	
  plexus	
  block	
  compared	
  with	
  plain	
  bupivacaine	
  spinal	
  anesthesia	
  for	
  hip	
  fractures	
  in	
  the	
  elderly.	
  Reg	
  Anesth	
  Pain	
  Med.	
  Mar-­‐Apr	
  2000;25(2):158-­‐162.	
  4.	
  de	
  Visme	
  V.	
  Peripheral	
  blocks	
  of	
  the	
  lower	
  limb	
  for	
  repair	
  of	
  fractured	
  neck	
  of	
  femur.	
  Br	
  J	
  Anaesth.	
  Sep	
  1998;81(3):483-­‐484.	
  5.	
  Oh	
  JH,	
  Kim	
  WS,	
  Kim	
  JY,	
  Gong	
  HS,	
  Rhee	
  KY.	
  Continuous	
  intralesional	
  infusion	
  combined	
  with	
  interscalene	
  block	
  was	
  effective	
  for	
  postoperative	
  analgesia	
  after	
  arthroscopic	
  shoulder	
  surgery.	
  J	
  Shoulder	
  Elbow	
  Surg.	
  May-­‐Jun	
  2007;16(3):295-­‐299.	
  6.	
  Egol	
  KA,	
  Soojian	
  MG,	
  Walsh	
  M,	
  Katz	
  J,	
  Rosenberg	
  AD,	
  Paksima	
  N.	
  Regional	
  anesthesia	
  improves	
  outcome	
  after	
  distal	
  radius	
  fracture	
  fixation	
  over	
  general	
  anesthesia.	
  J	
  Orthop	
  Trauma.	
  Sep	
  2012;26(9):545-­‐549.	
  7.	
  Goldstein	
  RY,	
  Montero	
  N,	
  Jain	
  S,	
  Egol	
  KA,	
  Tejwani	
  NC.	
  Efficacy	
  of	
  popliteal	
  block	
  in	
  post-­‐operative	
  pain	
  control	
  after	
  ankle	
  fracture	
  fixation:	
  A	
  prospective	
  randomized	
  study.	
  J	
  Orthop	
  Trauma.	
  Jun	
  22	
  2012.	
  8.	
  Williams	
  BA,	
  Bottegal	
  MT,	
  Kentor	
  ML,	
  Irrgang	
  JJ,	
  Williams	
  JP.	
  Rebound	
  pain	
  scores	
  as	
  a	
  function	
  of	
  femoral	
  nerve	
  block	
  duration	
  after	
  anterior	
  cruciate	
  ligament	
  reconstruction:	
  retrospective	
  analysis	
  of	
  a	
  prospective,	
  randomized	
  clinical	
  trial.	
  Reg	
  Anesth	
  Pain	
  Med.	
  May-­‐Jun	
  2007;32(3):186-­‐192.	
  9.	
  DeMarco	
  JR,	
  Componovo	
  R,	
  Barfield	
  WR,	
  Liles	
  L,	
  Nietert	
  P.	
  Efficacy	
  of	
  augmenting	
  a	
  subacromial	
  continuous-­‐infusion	
  pump	
  with	
  a	
  preoperative	
  interscalene	
  block	
  in	
  outpatient	
  arthroscopic	
  shoulder	
  surgery:	
  a	
  prospective,	
  randomized,	
  blinded,	
  and	
  placebo-­‐controlled	
  study.	
  Arthroscopy.	
  May	
  2011;27(5):603-­‐610.	
  10.	
  Fredrickson	
  MJ,	
  Ball	
  CM,	
  Dalgleish	
  AJ.	
  Analgesic	
  effectiveness	
  of	
  a	
  continuous	
  versus	
  single-­‐injection	
  interscalene	
  block	
  for	
  minor	
  arthroscopic	
  shoulder	
  surgery.	
  Reg	
  Anesth	
  Pain	
  Med.	
  Jan-­‐Feb	
  2010;35(1):28-­‐33.	
  11.	
  Kean	
  J,	
  Wigderowitz	
  CA,	
  Coventry	
  DM.	
  Continuous	
  interscalene	
  infusion	
  and	
  single	
  injection	
  using	
  levobupivacaine	
  for	
  analgesia	
  after	
  surgery	
  of	
  the	
  shoulder.	
  A	
  double-­‐blind,	
  randomised	
  controlled	
  trial.	
  J	
  Bone	
  Joint	
  Surg	
  Br.	
  Sep	
  2006;88(9):1173-­‐1177.	
  12.	
  Ilfeld	
  BM,	
  Morey	
  TE,	
  Wright	
  TW,	
  Chidgey	
  LK,	
  Enneking	
  FK.	
  Continuous	
  interscalene	
  brachial	
  plexus	
  block	
  for	
  postoperative	
  pain	
  control	
  at	
  home:	
  a	
  randomized,	
  double-­‐blinded,	
  placebo-­‐controlled	
  study.	
  Anesth	
  Analg.	
  Apr	
  2003;96(4):1089-­‐1095,	
  table	
  of	
  contents.	
  	
  	
  